Omada Health, which provides digital health tools for patients with chronic conditions, raised $150 million by offering 7.9 million shares at $19, within the range of $18 to $20. At pricing, the company commands a fully diluted market value of $1.2 billion.
Omada launched its initial program in diabetes prevention and weight health in 2012, and now offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address MSK conditions; its GLP-1 Care Tracks; and behavioral health support across all programs. As of March 31, 2025, Omada had more than 2,000 customers and over 679,000 total members enrolled in one or more programs, having supported over one million members since launch.
Omada Health plans to list on the Nasdaq under the symbol OMDA. Morgan Stanley, Goldman Sachs, J.P. Morgan, Barclays, and Evercore ISI acted as joint bookrunners on the deal.
